Plus Therapeutics PSTV Stock
Plus Therapeutics Price Chart
Plus Therapeutics PSTV Financial and Trading Overview
| Plus Therapeutics stock price | 0.51 USD |
| Previous Close | 0.54 USD |
| Open | 0.54 USD |
| Bid | 0.39 USD x 200 |
| Ask | 0.68 USD x 200 |
| Day's Range | 0.52 - 0.56 USD |
| 52 Week Range | 0.16 - 2.31 USD |
| Volume | 3.54M USD |
| Avg. Volume | 21.49M USD |
| Market Cap | 54.8M USD |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 USD |
PSTV Valuation Measures
| Enterprise Value | 46.9M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.26800972 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 10.307306 |
| Price/Book (mrq) | 16.730303 |
| Enterprise Value/Revenue | 8.821 |
| Enterprise Value/EBITDA | -3.86 |
Trading Information
Plus Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.81 |
| 52-Week Change | -59.090% |
| S&P500 52-Week Change | 20.77% |
| 52 Week High | 2.31 USD |
| 52 Week Low | 0.16 USD |
| 50-Day Moving Average | 0.56 USD |
| 200-Day Moving Average | 0.68 USD |
PSTV Share Statistics
| Avg. Volume (3 month) | 21.49M USD |
| Avg. Daily Volume (10-Days) | 9.85M USD |
| Shares Outstanding | 99.26M |
| Float | 98.86M |
| Short Ratio | 0.05 |
| % Held by Insiders | 1.91% |
| % Held by Institutions | 1.29% |
| Shares Short | 1.94M |
| Short % of Float | 1.94% |
| Short % of Shares Outstanding | 1.94% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | June 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -110.64% |
| Gross Margin | -51.32% |
| EBITDA Margin | -228.54% |
Management Effectiveness
| Return on Assets (ttm) | -74.047% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 5.32M USD |
| Revenue Per Share (ttm) | 0.33 USD |
| Quarterly Revenue Growth (yoy) | 8.69% |
| Gross Profit (ttm) | -2729000 USD |
| EBITDA | -12152000 USD |
| Net Income Avi to Common (ttm) | -19027000 USD |
| Diluted EPS (ttm) | -1.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.88M USD |
| Total Cash Per Share (mrq) | 0.07 USD |
| Total Debt (mrq) | 30K USD |
| Total Debt/Equity (mrq) | 0.99 USD |
| Current Ratio (mrq) | 1.259 |
| Book Value Per Share (mrq) | 0.033 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16861000 USD |
| Levered Free Cash Flow (ttm) | -16767375 USD |
Profile of Plus Therapeutics
| Country | United States |
| State | TX |
| City | Houston |
| Address | 2710 Reed Road |
| ZIP | 77051 |
| Phone | 737 255 7194 |
| Website | https://plustherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 21 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Q&A For Plus Therapeutics Stock
What is a current PSTV stock price?
Plus Therapeutics PSTV stock price today per share is 0.51 USD.
How to purchase Plus Therapeutics stock?
You can buy PSTV shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Plus Therapeutics?
The stock symbol or ticker of Plus Therapeutics is PSTV.
Which industry does the Plus Therapeutics company belong to?
The Plus Therapeutics industry is Biotechnology.
How many shares does Plus Therapeutics have in circulation?
The max supply of Plus Therapeutics shares is 137.43M.
What is Plus Therapeutics Price to Earnings Ratio (PE Ratio)?
Plus Therapeutics PE Ratio is now.
What was Plus Therapeutics earnings per share over the trailing 12 months (TTM)?
Plus Therapeutics EPS is -0.96 USD over the trailing 12 months.
Which sector does the Plus Therapeutics company belong to?
The Plus Therapeutics sector is Healthcare.
Plus Therapeutics PSTV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 22432.85 USD — |
-1.21
|
7.17B USD — | 22231.15 USD — | 22643.01 USD — | — - | 7.17B USD — |
| US Tech Capital Market Composite RCMP | 119.39 USD — |
+1.12
|
— — | 116.62 USD — | 120.38 USD — | — - | — — |
| US Tech Health Care IXHC | 1154.07 USD — |
+0.73
|
— — | 1138.72 USD — | 1157.89 USD — | — - | — — |
- {{ link.label }} {{link}}